2.37
price up icon14.49%   0.30
pre-market  プレマーケット:  2.37  
loading
前日終値:
$2.07
開ける:
$2.11
24時間の取引高:
5.61M
Relative Volume:
2.44
時価総額:
$517.09M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-8.4643
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+25.40%
1か月 パフォーマンス:
+29.51%
6か月 パフォーマンス:
+75.56%
1年 パフォーマンス:
+69.29%
1日の値動き範囲:
Value
$2.07
$2.37
1週間の範囲:
Value
$1.90
$2.37
52週間の値動き範囲:
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
167
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
2.37 517.09M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
167.53 75.58B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.24 41.78B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.10 41.53B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
21.82 24.72B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
145.88 14.77B 2.24B 385.90M 440.10M 3.73

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
Jan 21, 2025

Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9%Should You Buy? - MarketBeat

Jan 21, 2025
pulisher
Jan 20, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat

Jan 20, 2025
pulisher
Jan 18, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com

Jan 18, 2025
pulisher
Jan 18, 2025

Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat

Jan 16, 2025
pulisher
Jan 16, 2025

Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

HC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Akebia announces ‘multiple positive business updates’ - Yahoo Finance

Jan 14, 2025
pulisher
Jan 14, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Jane Street Group LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Vafseo tablets start U.S. shipment, Akebia plans Phase 3 trial - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

Akebia Therapeutics Announces Multiple Positive Business Updates - citybiz

Jan 13, 2025
pulisher
Jan 13, 2025

Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan

Jan 13, 2025
pulisher
Jan 10, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Jan 10, 2025
pulisher
Jan 08, 2025

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald

Jan 08, 2025
pulisher
Jan 07, 2025

Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com - MarketBeat

Jan 07, 2025
pulisher
Jan 05, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC - Defense World

Jan 05, 2025
pulisher
Jan 04, 2025

Geode Capital Management LLC Has $6.28 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

New Strong Sell Stocks for January 3rd - Yahoo Finance

Jan 03, 2025
pulisher
Jan 02, 2025

Akebia Therapeutics Awards Inducement Stock Options to New Employee at $1.90 Per Share - StockTitan

Jan 02, 2025
pulisher
Dec 31, 2024

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expands By 21.7% - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - MarketBeat

Dec 31, 2024
pulisher
Dec 30, 2024

State Street Corp Purchases 683,287 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Dec 30, 2024
pulisher
Dec 30, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street Corp - Defense World

Dec 30, 2024
pulisher
Dec 29, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Dec 29, 2024
pulisher
Dec 27, 2024

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com

Dec 27, 2024
pulisher
Dec 21, 2024

Wellington Management Group LLP Takes $534,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

High Growth Tech Stocks To Watch In December 2024 - Simply Wall St

Dec 20, 2024
pulisher
Dec 20, 2024

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance

Dec 20, 2024
pulisher
Dec 19, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 18, 2024

Akebia Therapeutics CEO to Present Vafseo Launch Updates at J.P. Morgan Healthcare Conference 2024 - StockTitan

Dec 18, 2024
pulisher
Dec 17, 2024

Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan

Dec 17, 2024
pulisher
Dec 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 08, 2024

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald

Dec 08, 2024
pulisher
Dec 07, 2024

Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online

Dec 07, 2024
pulisher
Dec 05, 2024

New Strong Sell Stocks for December 5th - Yahoo Finance

Dec 05, 2024
pulisher
Dec 04, 2024

Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com

Dec 04, 2024

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.10
price up icon 2.14%
$12.04
price up icon 0.17%
$94.05
price up icon 2.82%
$126.50
price up icon 0.24%
$11.33
price up icon 0.27%
$145.88
price up icon 1.83%
大文字化:     |  ボリューム (24 時間):